XML 32 R21.htm IDEA: XBRL DOCUMENT v3.25.1
Segment Information
 3 Months Ended
Mar. 31, 2025
Segment Reporting [Abstract]  
Segment Information Segment Information
The Company operates as one reportable segment in the United States, which includes all activities related to the development and commercialization of its DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases.
The Company's Chief Executive Officer (CEO) is its Chief Operating Decision Maker (CODM), responsible for allocating resources and assessing Company performance using aggregated financial information. Utilizing aggregated financial information enables the CODM to determine the most appropriate resource allocation across the organization, research and development projects or other initiatives consistent with the Company's corporate objectives. The CODM primarily uses total net loss as reported on the statements of operations and comprehensive loss to measure segment loss, supplemented by certain additional significant expense details reflected in the table below. The measure of segment assets is reported on the consolidated balance sheet as total assets.
Detailed information regarding the Company's single operating segment's revenues, expenses and operating loss are as follows:
Three Months Ended March 31,
20252024
Revenue from collaborative arrangements $65,343 $— 
Less:
Research and development:
     INO-31073,507,342 7,645,664 
     INO-3112 and other Immuno-oncology1,315,084 2,020,750 
     Other programs (a)107,425 623,666 
     Engineering and device-related5,061,810 3,751,261 
     Stock-based compensation553,394 1,060,487 
     Other unallocated expenses 5,545,847 5,811,962 
General and administrative9,024,970 10,571,179 
Total operating expenses25,115,872 31,484,969 
Interest income808,077 1,500,290 
Interest expense— (177,833)
Change in fair value of common stock warrant liability3,712,872 — 
Gain (loss) on investment in affiliated entity695,131 (126,018)
Net unrealized gain on available-for-sale equity securities140,234 500,877 
Other expense, net(482)(682,218)
Net loss$(19,694,697)$(30,469,871)

(a) Net of contributions received from grant agreements and recorded as contra-research and development expense.